Günther R. Adolf - Concepedia

Author

Günther R. Adolf

Also Known As

G Adolf, G R Adolf, G. ADOLF, G. Adolf, G. R. Adolf, G.R. Adolf, Gunther R. Adolf, Günther R. Adolf, GÜNTHER R. ADOLF, GÜNther Adolf

117

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (Austria)Boehringer Ingelheim (Germany)University of Graz

About

Günther R. Adolf is an author at Boehringer Ingelheim (Austria) specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	30	2.9K
2	Allergy	5	5	180
3	Natural Sciences	3	3	161
4	Biochemistry	2	2	106
5	Health Sciences	1	1	78

Günther R. Adolf

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo Martin Steegmaier, Matthias Hoffmann, Anke Baum, Current Biology Tumor BiologyBi 2536MedicineReceptor Tyrosine KinaseInhibits Tumor Growth	2007	839
HLA class II induction in human islet cells by interferon-γ plus tumour necrosis factor or lymphotoxin Ricardo Pujol‐Borrell, Ian Todd, Mala Doshi, Nature InflammationHistocompatibilityHuman Islet CellsTumour Necrosis FactorImmunodeficiencies	1987	446
BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity Dorothea Rudolph, Martin Steegmaier, Matthias Hoffmann, Clinical Cancer Research	2009	388
Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. Gerrit Koopman, Karl‐Heinz Heider, E Horst, The Journal of Experimental Medicine Lymphoid NeoplasiaExon V6Aggressive Non-hodgkinImmunologyTumor Immunity	1993	305
Identification of tumor antigens in renal cell carcinoma by serological proteome analysis Christoph Klade, Tilman Voss, E. Krystek, PROTEOMICS Renal PathologyImmunologyPathologyTumor BiologyTumor Antigens	2001	204
Comparison of immunohistochemistry and RT‐PCR for detection of CD44v‐expression, a new prognostic factor in human breast cancer Peter Dall, Karl‐Heinz Heider, Hans‐Peter Sinn, International Journal of Cancer	1995	148
Molecular Cloning and Expression of Human and Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein Adolf Himmler, Ingrid Maurer-Fogy, Martin Krönke, DNA and Cell Biology	1990	133
A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies Karl‐Heinz Heider, Kerstin Kiefer, Thorsten Zenz, Blood	2011	103
Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin Katrin Friedbichler, Marco H. Hofmann, Monika Kroez, Molecular Cancer Therapeutics Chemoprevention StrategyImmunologyBiological TherapyImmunotherapyTumor Biology	2013	97
A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation Irene C. Waizenegger, Anke Baum, Steffen Steurer, Molecular Cancer Therapeutics Braf-mutant MelanomasPathologyCancer BiologyTumor BiologyReceptor Tyrosine Kinase	2016	89

Page 1